Mylan Pharmaceuticals, Inc. has announced a recall of one batch of its 100 units/mL insulin glargine injection due to a potential missing label on some vials, according to a press release.
The recall affects batch BF21002800 of Mylan’s unbranded insulin glargine-yfgn, a long-acting insulin analog used to improve glycemic control for adults and children with type 1 diabetes and adults with type 2 diabetes. The recall affects only the unbranded insulin glargine-yfgn and not the branded Semglee vial.
For patients receiving more than one type of insulin, the missing label could lead them to